drugset
drugset / Trial / NCT06886126

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

NCT06886126 ↗

Phase 2 Recruiting 240 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.

Timeline

Start
2025-02-07
Primary completion
2025-09-23
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM1005 Unknown — Subcutaneous

Indications

obesity disorder